Guide

Corrected 4 August 2026

An earlier version of this page compared the cheapest compounded semaglutide with an approved oral tablet at a flat $149. That is the price at 1.5 and 4 mg only. The 9 and 25 mg maintenance doses are $299, and the $149 rate on 4 mg ends on 31 August 2026.

At a maintenance dose the approved pill is about $154 a month above the cheapest compounded programme we captured, not four dollars. We publish this as COR-013 because it is the starter-price error this site documents in others.

This figure has a stated end date

The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.

We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.

Your GLP-1 Was Denied: The Four Reasons, and Which Are Worth Appealing

There are four common denial reasons and only two are usually worth appealing. Missing documentation and step therapy are resolvable. An employer plan that excludes weigh

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-08-03Updated 2026-08-03Sources captured 2026-08-03Medically reviewed not yet — why

Direct answer

There are four common denial reasons and only two are usually worth appealing. Missing documentation and step therapy are resolvable. An employer plan that excludes weight-loss drugs is a purchasing decision, not a clinical one, and clinical evidence does not address it.

Answer last reviewed: 2026-08-03

Which denial did you get?

The four reasons, and the realistic outcome of each
Denial reason	What it means	Worth appealing?
Insufficient documentation	BMI, weight history or comorbidities missing	Yes — usually resolvable
Step therapy required	Try a cheaper option first	Yes — document prior attempts
Not on formulary, weight benefit excluded	Employer did not buy the benefit	Rarely reversed
Medicare or Medicaid	Savings card barred by federal law	No — use the Bridge

Where to spend your effort

Two of the four are worth working. The third is not, and recognising it early saves weeks: if your employer did not purchase an obesity-drug benefit, no amount of clinical documentation changes that, because it was never a clinical decision.

The tell is the wording. “Not medically necessary” is a clinical judgement you can answer. “Benefit not covered under your plan” or “excluded” is a contract term you cannot.

What actually strengthens an appeal?

Documented weight history over time, not a single reading.
Comorbidities coded — hypertension, dyslipidaemia, prediabetes, sleep apnoea.
Prior attempts that failed, dated, which is what answers step therapy.
A peer-to-peer review between your prescriber and the plan's clinician.

One route worth raising specifically: tirzepatide carries an approved indication for moderate-to-severe obstructive sleep apnoea in adults with obesity. Many plans that exclude obesity drugs do cover apnoea therapy. That is a different argument, not a workaround, and it requires a genuine diagnosis.

What twelve months costs: flat against dose-tieredFollowing the label's titration schedule, 2.5 mg to a maintenance dose

Show this figure as a table

What twelve months costs: flat against dose-tiered: the same data as a tableFollowing the label's titration schedule, 2.5 mg to a maintenance dose

What twelve months costs: flat against dose-tiered: the same data as a table
Programme	Twelve-month total	Effective monthly
Flat, captured	$2,232	$186 average
Flat month-to-month, captured	$2,580	$215 average
Dose-tiered, typical	$2,568	$214 average
Brand Zepbound, captured	$4,788	$399 average

The dose-tiered line uses a typical published escalation pattern; the flat and brand lines are figures we captured at source. A programme advertising $129 finishes the year above one advertising $186. That crossover is the argument this whole site is built on. How we record price structure.

What does it cost if the appeal fails?

Semaglutide by route and dose, re-confirmed at source 4 August 2026
Route	Monthly	Twelve months	Evidence
Commercial cover plus savings offer	$25	$300	Capped at $100/month in savings
Medicare GLP-1 Bridge	$50	$600	Reported
Approved oral tablet, 1.5 or 4 mg	$149	—	Captured at source — 4 mg rises to $199 after 31 Aug 2026
Approved oral tablet, 9 or 25 mg maintenance	$299	$3,588	Captured at source
Compounded, 12-month, flat at every dose	$145	$1,740	Captured at source
Compounded, month-to-month, flat	$165	$1,980	Captured at source
Brand Wegovy pen, new-patient intro	$199	—	First two fills only, to 31 Dec 2026
Brand Wegovy pen, 0.25–2.4 mg	$349	$4,188	Captured at source
Brand Wegovy HD 7.2 mg	$399	$4,788	Captured at source
Brand Wegovy, retail list	~$1,349	~$16,188	Third-party claim
Compounded tirzepatide, for comparison	$186	$2,232	Captured at source

Read the dose column. The approved oral tablet is a ladder, not a flat rate: $149 at 1.5 and 4 mg, $299 at 9 and 25 mg. We published it as a flat $149 and corrected that on 4 August 2026 — COR-013. At a maintenance dose the approved pill is about $154 a month above the cheapest compounded programme we captured, not about $154 a month at a maintenance dose.

At $149 for an approved oral tablet, the cash comparison is no longer what it was when compounding was the only affordable route. Price the approved options before assuming compounded is the answer.

Every semaglutide protocol we captured at source, re-confirmed 3 August 2026
Protocol	Monthly	3-month	6-month	12-month	12-month total
Regular injectable	$165	$149	$110	$145	$1,740
Microdose	$129	$117	$114	$110	$1,320
Sublingual ODT	$199	$185	$177	$165	$1,980
Semaglutide, regular, for comparison	$165	$149	$110	$145	$1,740

Flat at every covered dose within each protocol. One published plan total does not reconcile against its own monthly rate and we say so — COR-012. Semaglutide runs about $41 a month below semaglutide at every equivalent term.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Six tests, thirty providers, scored from the datasetComputed from the dataset on 2026-08-03 · 30 providers evaluated

Six tests, thirty providers, scored from the dataset
Provider	Captured at source	Publishes a maintenance-dose price	One published structure	Names its fulfilling pharmacy	Answered all four disclosure questions	No figure we had to withdraw	Score
Mochi Health	Yes	Yes	Yes	Yes	—	Yes	5 of 6
NexLife	Yes	Yes	Yes	Yes	—	Yes	5 of 6
Fifty 410	Yes	—	Yes	—	—	Yes	3 of 6
LillyDirect	Yes	—	Yes	—	—	Yes	3 of 6
Trimi	Yes	—	Yes	—	—	Yes	3 of 6
Calibrate	—	—	Yes	—	—	Yes	2 of 6
Enhance.MD	—	—	Yes	—	—	Yes	2 of 6
Form Health	—	—	Yes	—	—	Yes	2 of 6

Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.

The result, as of 2026-08-03

No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.

That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.

Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: any schedule described comes from approved labelling, and your prescriber sets your regimen.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Why 'cheapest' needs a definition attached

Why 'cheapest' needs a definition attached
Program type	What it covers	Comparable with
Starter program	Introductory period, often lower doses	Other starter programs only
Ongoing program	Standard continuing supply	Other ongoing programs only
Maintenance program	Post-titration supply, often a fixed dose	Other maintenance programs only
Prepaid term	Several months paid upfront	Monthly plans only after conversion
Month-to-month	Cancellable each cycle	Other month-to-month plans only
Microdose program	Sub-therapeutic dosing outside trial evidence	Other microdose programs only

Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

Why was my Wegovy prior authorisation denied?

The four common reasons are missing documentation, step therapy, an employer plan that excludes weight-loss drugs, and Medicare or Medicaid enrolment. Only the first two are usually resolvable.

Can I appeal a formulary exclusion?

Rarely successfully. An excluded weight-loss benefit is an employer purchasing decision rather than a clinical judgement, so clinical documentation does not address it.

What are my options if the appeal fails?

An approved oral semaglutide tablet at $149, brand Wegovy at $349 through NovoCare, or compounded from $145 with no trial of its own.

Is there another indication that might be covered?

Tirzepatide carries an approved indication for moderate-to-severe obstructive sleep apnoea in adults with obesity, and many plans cover apnoea therapy while excluding obesity drugs.

Provider ranking methodologyCore & Trust
GLP-1 total cost calculatorTools
Download the pricing recordsData
Ro Body vs Hims & HersComparisons
Hims & Hers vs Henry MedsComparisons
Brand-Name vs Compounded TirzepatidePillar / Money
Tirzepatide for Type 2 DiabetesResearch
Hims & Hers Tirzepatide ReviewProviders
Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
Cheapest FDA-Approved vs Compounded GLP-1 OptionsJournal

Cite this pageCC BY 4.0

GLP-1 Semaglutide Rx. “Your GLP-1 Was Denied: The Four Reasons, and Which Are Worth Appealing.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/semaglutide-insurance-denied-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.